In vivo efficacy of sulphadoxine-pyrimethamine for the treatment of asymptomatic parasitaemia in pregnant women in Machinga District, Malawi

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Gutman, Julie ^a   Mwandama, Dyson ^b   Wiegand, Ryan E ^a   Abdallah, Joseph ^c   Iriemenam, Nnaemeka C ^a   Shi, Ya Ping ^a   Mathanga, Don P ^b   Skarbinski, Jacek ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF MALAWI   (Malawi)

^c EMORY UNIVERSITY   (United States)

Author keywords

in vivo; Intermittent preventive treatment; Malaria; Malawi; Pregnancy; Sulphadoxine pyrimethamine

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; HEMOGLOBIN; PYRIMETHAMINE PLUS SULFADOXINE; ANTIMALARIAL AGENT; DRUG COMBINATION; FANASIL, PYRIMETHAMINE DRUG COMBINATION; PROTOZOAL PROTEIN; PYRIMETHAMINE; SULFADOXINE;

ADOLESCENT; ADULT; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; ASYMPTOMATIC INFECTION; BED NET; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DHFR GENE; DHPS GENE; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GENE MUTATION; GESTATIONAL AGE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALARIA CONTROL; MALARIA FALCIPARUM; MALAWI; MATERNAL TREATMENT; MICROBIAL GENE; MULTIGRAVIDA; NONHUMAN; PARASITE IDENTIFICATION; PARASITE PREVALENCE; PLASMODIUM FALCIPARUM; PREGNANT WOMAN; PRENATAL CARE; PRIMIGRAVIDA; REINFECTION; SURVIVAL RATE; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; MALARIA, FALCIPARUM; METABOLISM; PARASITEMIA; PARASITOLOGY; PARITY; POLYMERASE CHAIN REACTION; PREGNANCY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIMALARIALS; ASYMPTOMATIC INFECTIONS; DIHYDROPTEROATE SYNTHASE; DRUG COMBINATIONS; DRUG RESISTANCE; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALAWI; PARASITEMIA; PARITY; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PREGNANCY; PROTOZOAN PROTEINS; PYRIMETHAMINE; SULFADOXINE; TETRAHYDROFOLATE DEHYDROGENASE; YOUNG ADULT;

EID: 84934993978     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0710-7     Document Type: Article

References (34)

1. Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007;7:93-104.
2. ter Kuile FO, van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy. JAMA. 2007;297:2603-16.
3. Kayentao K, Kodio M, Newman RD, Maiga H, Doumtabe D, Ongoiba A, et al. Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali. J Infect Dis. 2005;191:109-16.
4. Parise ME, Ayisi JG, Nahlen BL, Schultz LJ, Roberts JM, Misore A, et al. Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg. 1998;59:813-22.
5. WHO Malaria Policy Advisory Committee Secretariat. Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of September 2012 meeting. Malar J. 2012;11:424.
6. Taylor SM, Antonia A, Chaluluka E, Mwapasa V, Feng G, Molyneux ME, et al. Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant Plasmodium falciparum: clinical outcomes from the QuEERPAM study. Clin Infect Dis. 2012;55:42-50.
7. Taylor SM, Antonia A, Feng G, Mwapasa V, Chaluluka E, Molyneux M, et al. Adaptive evolution and fixation of drug-resistant Plasmodium falciparum genotypes in pregnancy-associated malaria: 9-year results from the QuEERPAM study. Infect Genet Evol. 2012;12:282-90.
8. Kayentao K, Garner P, van Eijk AM, Naidoo I, Roper C, Mulokozi A, et al. Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in africa: systematic review and meta-analysis. JAMA. 2013;309:594-604.
9. Feng G, Simpson JA, Chaluluka E, Molyneux ME, Rogerson SJ. Decreasing burden of malaria in pregnancy in Malawian women and its relationship to use of intermittent preventive therapy or bed nets. PLoS ONE. 2010;5:e12012.
10. Harrington WE, Mutabingwa TK, Muehlenbachs A, Sorensen B, Bolla MC, Fried M, et al. Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proc Natl Acad Sci U S A. 2009;106:9027-32.
11. Harrington W, Mutabingwa T, Kabyemela E, Fried M, Duffy P. Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. Clin Infect Dis. 2011;53:224-30.
12. Minja D, Schmiegelow C, Mmbando B, Boström S, Oesterholt M, Magistrado P, et al. Infections with Plasmodium falciparum sextuple dihydrofolate reductase/dihydropteroate synthetase allelic haplotypes during pregnancy are associated with decreased birth weight in Korogwe, Tanzania. Emerg Inf Dis. 2013,19 Sept http://dx.doi.org/10.3201/eid1909.130133
13. Gutman J, Kalilani L, Taylor S, Zhou Z, Wiegand RE, Thwai KL, et al. Plasmodium falciparum dhps-581G mutation reduces the effectiveness of sulfadoxine-pyrimethamine intermittent preventive therapy in Malawian pregnant women. JID 2015. Epub ahead of print.
14. Msyamboza K, Amanor A, Kazembe P, Brabin B, Meshnick S, Mwapasa V. In-vivo parasitological response to sulfadoxine-pyrimethamine in pregnant women in southern Malawi. Malawi Med J. 2007;19:11-3.
15. WHO. Standard protocol for measuring efficacy of antimalarial drugs in high transmission settings. Geneva: World Health Organization; 2003.
16. Iriemenam N, Shah M, Gatei W, van Eijk A, Ayisi J, Kariuki S, et al. Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum parasites from pregnant women in western Kenya. Malar J. 2012;11:134.
17. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis. 2002;185:380-8.
18. WHO. Recommended Genotyping Procedures (RGPs) to identify parasite populations, Developed after an informal consultation organized by the Medicines for Malaria Venture and cosponsored by the World Health Organization, 29-31 May 2007, Amsterdam, The Netherlands. 2007. http://www.who.int/malaria/publications/atoz/rgptext-sti.pdf, accessed Dec 9, 2014.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assn. 1958;53:457-81.
20. Groenwold RH, Donders AR, Roes KC, Harrell Jr FE, Moons KG. Dealing with missing outcome data in randomized trials and observational studies. Am J Epidemiol. 2012;175:210-7.
21. Cox DR. Regression models and life tables. J Royal Stat Soc Ser B. 1972;20:187-220.
22. Schwartz G. Estimating the dimension of a model. Ann Stat. 1978;6:461-4.
23. Wickham H. ggplot2: elegant graphics for data analysis. New York: Springer; 2009.
24. WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009.
25. WHO. Updated WHO policy recommendation: intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP). http://www.who.int/entity/malaria/publications/atoz/who-iptp-sp-policy-recommendation/en/index.html
26. Gutman J, Mwandama D, Wiegand R, Ali D, Mathanga DP, Skarbinski J. Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine in pregnancy on maternal and infant birth outcomes in Machinga District, Malawi. J Inf Dis. 2013;208:907-16.
27. Arinaitwe E, Ades V, Walakira A, Ninsiima B, Mugagga O, Patil TS, et al. Intermittent preventive therapy with sulfadoxine-pyrimethamine for malaria in pregnancy: a cross-sectional study from Tororo, Uganda. PLoS ONE. 2013;8:e73073.
28. Tan KR, Katalenich BL, Mace KE, Nambozi M, Taylor SM, Meshnick SR, et al. Efficacy of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy, Mansa, Zambia. Malar J. 2014;13:227.
29. Mace K, Chalwe V, Katalenich BL, Nambozi M, Mubikayi L, Mulele CK, et al. Evaluation of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy: a retrospective birth outcomes study-Mansa, Zambia. Malar J. 2015;14:69.
30. White N. Intermittent presumptive treatment for malaria. PLoS Med. 2005;2:e3.
31. Cohee L, Kalilani-Phiri L, Boudova S, Joshi S, Mukadam R, Seydel K, et al. Submicroscopic malaria infection during pregnancy and the impact of intermittent preventive treatment. Malar J. 2014;13:274.
32. Tagbor H, Bruce J, Agbo M, Greenwood B, Chandramohan D. Intermittent screening and treatment versus intermittent preventive treatment of malaria in pregnancy: a randomised controlled non-inferiority trial. PLoS ONE. 2010;5:e14425.
33. Coulibaly S, Kayentao K, Taylor S, Guirou E, Khairallah C, Guindo N, et al. Parasite clearance following treatment with sulphadoxine-pyrimethamine for intermittent preventive treatment in Burkina-Faso and Mali: 42-day in vivo follow-up study. Malar J. 2014;13:41.
34. Moussiliou A, De Tove YS-S, Doritchamou J, Luty A, Massougbodji A, Alifrangis M, et al. High rates of parasite recrudescence following intermittent preventive treatment with sulphadoxine-pyrimethamine during pregnancy in Benin. Malar J. 2013;12:195.